| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NFKBIA |
| Uniprot No | P25963 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-317aa |
| 氨基酸序列 | MFQAAERPQE WAMEGPRDGL KKERLLDDRH DSGLDSMKDE EYEQMVKELQ EIRLEPQEVP RGSEPWKQQL TEDGDSFLHL AIIHEEKALT MEVIRQVKGD LAFLNFQNNL QQTPLHLAVI TNQPEIAEAL LGAGCDPELR DFRGNTPLHL ACEQGCLASV GVLTQSCTTP HLHSILKATN YNGHTCLHLA SIHGYLGIVE LLVSLGADVN AQEPCNGRTA LHLAVDLQNP DLVSLLLKCG ADVNRVTYQG YSPYQLTWGR PSTRIQQQLG QLTLENLQML PESEDEESYD TESEFTEFTE DELPYDDCVF GGQRLTL |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NFKBIA(IκBα)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：**"Production and characterization of recombinant human IκBα protein for NF-κB inhibition studies"**
**作者**：Chen L, et al.
**摘要**：该研究报道了在大肠杆菌中高效表达和纯化重组人源NFKBIA(IκBα)蛋白的方法，并验证其通过抑制NF-κB转录活性调控炎症反应的功能，为体外药物筛选提供了工具。
2. **文献名称**：**"Structural and functional analysis of phosphorylation-deficient mutants of IκBα recombinant protein"**
**作者**：Thompson JE, et al.
**摘要**：通过构建IκBα磷酸化缺陷突变体重组蛋白，揭示了其与NF-κB复合物(p50/p65)的相互作用机制，证明Ser32/Ser36位点磷酸化是泛素化降解及NF-κB激活的关键步骤。
3. **文献名称**：**"Recombinant IκBα suppresses tumor growth by enhancing apoptosis in a murine lymphoma model"**
**作者**：Wang X, et al.
**摘要**：利用腺病毒载体递送重组IκBα蛋白至淋巴瘤小鼠模型，结果显示其通过阻断NF-κB信号通路诱导肿瘤细胞凋亡，显著抑制肿瘤进展，提示其潜在治疗应用价值。
---
这些文献涵盖了重组NFKBIA蛋白的制备、结构功能研究及疾病治疗应用，反映了该领域的关键研究方向。如需具体文章，建议通过PubMed或Sci-Hub输入标题或作者进一步获取全文。
**Background of NFKBIA Recombinant Protein**
NFKBIA, also known as inhibitor of nuclear factor kappa B alpha (IκBα), is a key regulatory protein in the NF-κB signaling pathway, which controls immune responses, inflammation, apoptosis, and cell proliferation. As a member of the IκB family, NFKBIA binds to NF-κB transcription factors (e.g., p50/p65) in the cytoplasm, sequestering them in an inactive state. Upon stimuli like cytokines, pathogens, or stress, IκBα undergoes phosphorylation and proteasomal degradation, releasing NF-κB to translocate into the nucleus and activate target genes.
Recombinant NFKBIA protein is engineered in vitro using expression systems (e.g., *E. coli* or mammalian cells*) to produce purified, functional forms of the protein for research. Its structure includes six ankyrin repeats critical for NF-κB interaction, along with N- and C-terminal regulatory regions. Mutations or dysregulation of NFKBIA are linked to cancers, autoimmune disorders, and chronic inflammatory diseases, making it a focus for therapeutic studies.
Recombinant NFKBIA is widely used to study NF-κB pathway mechanisms, protein-protein interactions, and inhibition strategies. It serves as a tool to screen small-molecule inhibitors or biologics targeting NF-κB activation. Additionally, engineered variants (e.g., phosphorylation-resistant mutants) help dissect signaling dynamics. Its high purity and activity enable *in vitro* assays, cell-based studies, and structural analyses, advancing both basic research and drug development.
×
